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A major advance in understanding the role of 
various T cell subsets in disease has been the 
recent identification of the Th17 subset, char-
acterized by the production of IL-17A (IL-17), 
as well as the related IL-17F cytokine (Weaver 
et al., 2006). Just as with the Th1 and Th2 
subsets, whose development and propagation 
are mediated by specific cytokines, Th17 de-
velopment is selectively induced by a combi-
nation of IL-6 and TGF-, whereas the IL-12 
family member IL-23 supports Th17 propaga-
tion (Chen and O’Shea, 2008). The ability of 
IL-6 to divert TGF-–stimulated T cells away 
from regulatory T cell differentiation and to-
ward Th17 cell differentiation, as well as the 
distinct roles of IL-12 and IL-23 in supporting 
Th1 and Th17 propagation, respectively, em-
phasizes the high degree of regulation involved 
in  T  cell  development  and  function  under 
various physiological states.
Th17 responses appear to be physiologi-
cally important in pulmonary bacterial immu-
nity as well as immunity to certain intestinal 
pathogens (Khader et al., 2007). The specific 
role of IL-17 and other cytokines produced 
by Th17 cells in these responses remains to be 
completely elucidated, though direct effects 
on epithelial cells as well as recruitment of 
neutrophils seem to be important factors, de-
pending on the site and nature of the infec-
tion  (Khader  et  al.,  2007).  Pathologically, 
Th17 responses are involved in certain in-
flammatory and autoimmune diseases, includ-
ing inflammatory bowel disease, rheumatoid 
arthritis, autoimmune iritis, and central ner-
vous system autoimmune syndromes (Bettelli 
et al., 2007). CD8 T cells and non–T cells 
have been reported to produce Th17 cyto-
kines (Weaver et al., 2007), including IL-17, 
but the role of non–T cell–derived IL-17 re-
mains to be further defined.
The immune system can act as an extrinsic 
suppressor of tumors, and the importance of 
Th1, characterized by IFN- and type 1 IFNs, 
in inhibiting tumor incidence and growth has 
been  established  (Kaplan  et  al.,  1998;  Dunn   
et al., 2006). Recent studies, however, have 
also demonstrated a critical role of certain im-
mune cells, via production of specific cytokines 
CORRESPONDENCE  
H. Yu:  
hyu@coh.org  
OR  
D. Zeng:  
dzeng@coh.org  
OR  
D. Pardoll:  
dmpardol@jhmi.edu
Abbreviations used: MEF, mouse 
embryonic fibroblast; phospho-
Stat3, phosphorylated Stat3.
L. Wang and T. Yi contributed equally to this paper.
IL-17 can promote tumor growth  
through an IL-6–Stat3 signaling pathway
Lin Wang,1,4 Tangsheng Yi,2,3,4 Marcin Kortylewski,1 Drew M. Pardoll,5 
Defu Zeng,2,3 and Hua Yu1
1Department of Cancer Immunotherapeutics and Tumor Immunology, 2Department of Hematology and Hematopoietic Cell 
Transplantation, 3Department of Diabetes and Metabolic Diseases Research, and 4Graduate School of Biological Science, 
Beckman Research Institute at City of Hope Medical Center, Duarte, CA 91010
5Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231
Although the Th17 subset and its signature cytokine, interleukin (IL)-17A (IL-17), are impli-
cated in certain autoimmune diseases, their role in cancer remains to be further explored.  
IL-17 has been shown to be elevated in several types of cancer, but how it might contribute 
to tumor growth is still unclear. We show that growth of B16 melanoma and MB49 bladder 
carcinoma is reduced in IL-17/ mice but drastically accelerated in IFN-/ mice, contrib-
uted to by elevated intratumoral IL-17, indicating a role of IL-17 in promoting tumor 
growth. Adoptive transfer studies and analysis of the tumor microenvironment suggest that 
CD4+ T cells are the predominant source of IL-17. Enhancement of tumor growth by IL-17 
involves direct effects on tumor cells and tumor-associated stromal cells, which bear IL-17 
receptors. IL-17 induces IL-6 production, which in turn activates oncogenic signal transducer 
and activator of transcription (Stat) 3, up-regulating prosurvival and proangiogenic genes. 
The Th17 response can thus promote tumor growth, in part via an IL-6–Stat3 pathway.
© 2009 Wang et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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and tumor angiogenesis (Bromberg et al., 1999; Yu et al., 
2007). Persistent activation of Stat3 in tumor cells and in tu-
mor-associated immune cells also promotes accumulation of 
tumor myeloid-derived suppressor cells and tumor regulatory 
T cells, leading to tumor immune suppression (Kortylewski 
et al., 2005). Although IL-17–producing T cells have been 
found in increased numbers within certain tumors (Miyahara 
et al., 2008; Sfanos et al., 2008; Zhang et al., 2008), it remains 
controversial whether IL-17 promotes or inhibits cancer pro-
gression (Numasaki et al., 2003; Numasaki et al., 2005;   
Muranski et al., 2008; Nam et al., 2008; Kryczek et al., 2009; 
Xiao et al., 2009; Zhang et al., 2009). Importantly, the un-
derlying mechanisms of IL-17 in modulating tumor growth 
is still poorly understood.
or growth factors, in promoting carcinogenesis and tumor 
growth (Colombo and Mantovani, 2005). This opposing role 
of the immune system in tumor immune surveillance and 
cancer promotion is exemplified by a pair of related cyto-
kines: although IL-12 clearly possesses antitumor activity via 
both NK activation and Th1/IFN- induction, IL-23 has 
been  found  to  promote  carcinogenesis  (Langowski  et  al., 
2006).  Specific  STAT  pathways  regulate  the  IL-12/IL-23 
balance, with Stat3 coordinately activating IL-23/p19 gene 
transcription while inhibiting expression of the IL-12/p35 
gene (Kortylewski et al., 2009). Similar to IL-23, IL-17 ex-
pression is also regulated by Stat3 (Chen et al., 2006), which 
is an oncogene persistently activated in tumor cells and tumor 
stromal cells, promoting tumor cell survival, proliferation, 
Figure 1.  IL-17 promotes tumor growth, which is mainly mediated by T cells. (A) 105 B16 tumor cells were injected subcutaneously into WT,  
IL-17/, IFN-/, and IFN-/IL-17/ B6 mice. Data represent means ± SEM (n = 12 mice per group from three independent experiments). (B) MB49 
tumor growth in WT, IL-17/, IFN-/, and IFN-/IL-17/ B6 mice (n = 8 mice from two experiments). (C and D) Intratumoral IL-17 promotes 
cancer metastasis. (C) MB49 tumor cells were injected subcutaneously into the four groups of mice as indicated, and lung colonies were enumerated  
3 wk later (n = 4; P = 0.01). (D) Representative photos of the lung tissues from each group with arrows indicating lung metastasis are shown. Bars: 
(top) 1,000 µm; (bottom) 500 µm. (E) IL-17–mediated tumor-promoting effects are mainly mediated by T cells. Rapid B16 tumor growth in Rag-2/ 
mice receiving adoptive transfer of IFN-/ T cells was observed compared with significantly reduced growth rates in mice receiving adoptive-trans-
ferred IFN-/IL-17/ T cells. Data represent means ± SEM (n = 11 mice from two experiments).JEM VOL. 206, July 6, 2009  1459
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RESULTS AND DISCUSSION
Th17 cells can promote tumor growth
We assessed the role of IL-17 in modulating tumor growth in 
mice with genetically ablated IL-17 alleles (IL-17 KO). Be-
cause IFN-–producing Th1 T cells generally provide anti-
tumor immunity (Kaplan et al., 1998; Dunn et al., 2006) and 
are known to restrain Th17 cell development (Harrington   
et al., 2005), we also evaluated tumor growth in IFN- KO 
mice and in IL-17IFN- double KO mice. Sex- and age-
matched WT, IL-17/, IFN-/, and IFN-/IL-17/ 
B6 mice were challenged with B16 melanoma. Results from 
these experiments showed that tumor growth rate was re-
duced in the B6 IL-17/ mice when compared with WT 
B6 controls (Fig. 1 A). As expected from the antitumor role 
of IFN- (Kaplan et al., 1998; Dunn et al., 2006), in B6 mice 
lacking IFN- alleles, B16 tumors appeared earlier and the 
tumor growth rate was drastically increased relative to the 
WT (Fig. 1 A). Importantly, in IFN-/IL-17/ mice, tumor 
growth  was  significantly  reduced  compared  with  IFN-/ 
mice (Fig. 1 A), supporting a tumor-promoting role of Th17 
cells in the B16 subcutaneous tumor model.
We also evaluated growth of the MB49 bladder carci-
noma in WT, IL-17/, IFN-/, and IFN-/IL-17/ 
mice. Similar to B16, we observed growth inhibition of MB49 
tumors in IL-17/ mice relative to WT controls (Fig. 1 B). 
Furthermore, MB49 tumor growth was significantly acceler-
ated in IFN-/ relative to WT mice. Ablating IL-17 di-
minished accelerated tumor growth caused by a lack of IFN- 
(Fig. 1 B). However, the tumor growth rate in the IFN-
/IL-17/ B6 mice was higher than in IL-17/ mice. 
Thus, the general pattern of tumor growth in IL-17/, IFN-
/, and IFN-/IL-17/ mice was similar for B16 and 
MB49 tumors despite their different tissue origins. Subcuta-
neous MB49 tumors also naturally metastasize to lungs; we 
therefore assessed whether levels of lung metastasis correlate 
with tumor size in the four groups of mice. Ablating IL-17 in 
both WT and IFN-/ mice was associated with a decreased 
number of lung metastases (Fig. 1, C and D).
To assess whether T cells were a primary source of IL-17 
for promoting tumor growth, we reconstituted Rag2/ 
mice by adoptive T cell transfer with purified T cells from 
IFN-/ mice that display high levels of IL-17 production 
(Fig. 2), or from IFN-/IL-17/ mice. Tumor growth in 
mice receiving IFN-/IL-17/ T cells was significantly 
reduced compared with mice given IFN-/ T cells (Fig. 1 E), 
suggesting that the increased tumor growth, caused by ele-
vated IL-17 production, was mainly contributed by T cells.
Reciprocal relationship between IL-17 and IFN- 
production in tumors
We performed intracellular cytokine staining and in vitro 
cytokine production assays to compare the cytokine pro-
file of CD4+ and CD8+ T cells in tumors harvested from 
WT,  IL-17/,  IFN-/,  and  IFN-/IL-17/  mice. 
IL-17 production in B16 tumors was markedly augmented 
in the absence of IFN-, with an increase in the number of   
Figure 2.  Reciprocal relationship between IFN- and IL-17 pro-
duction by tumor-infiltrating T lymphocytes. Single-cell suspen-
sions were prepared from B16 or MB49 tumors harvested 20 d after 
tumor implantation. (A) IL-17 expression in CD4+ T cells from B16 (top) 
or MB49 (bottom) tumors; flow cytometric patterns shown (one tumor 
per group) are representative of three independent experiments. Per-
centages are shown. (B) IL-17 secretion by intratumoral CD4+ T cells 
sorted from B16 tumors grown in WT, IL-17/, IFN-/, or IFN-
/IL-17/ mice was assessed by ELISA after a 24-h culture, combin-
ing results from three independent experiments of three to four pooled 
tumor samples (P = 0.001). Data represent means ± SEM. (C) Percent-
ages of CD4+ and CD8+ T cells within the total intratumoral leukocyte 
population harvested on days 20 (top row) and 14 (second from top 
row). (second from bottom row) IFN- expression in CD8+ T cells  
derived from tumors of WT or IL-17/ mice. (bottom row) IFN-  
expression by tumor-infiltrating CD4+ T cells (representative of three 
independent experiments). Percentages are shown. (D) Increased secre-
tion of IFN- by sorted tumor-infiltrating CD8+ (top) and CD4+ (bottom) 
T cells, combining results from three independent experiments of 
pooled tumor samples (P = 0.002). Data represent means ± SEM.  
TIL, tumor-infiltrating T lymphocytes.1460 TH17 RESPONSES PROMOTE TUMOR PROGRESSION VIA A STAT3 PATHWAY | Wang et al.
cence staining of phosphorylated Stat3 (phospho-Stat3) in 
situ. We observed reduced phospho-Stat3 levels in B16 tu-
mors grown in IL-17/ mice compared with WT controls. 
In addition, Stat3 activity was drastically increased in tumors 
grown in IFN-/ mice, suggesting an inhibitory role of IFN- 
on tumor Stat3 activation. Stat3 phosphorylation was dimin-
ished in tumors harvested from IFN-/IL-17/ compared 
with IFN-/ mice (Fig. 3 A). Immunofluorescence stain-
ing results were confirmed by Western blotting using an anti-
body for phospho-Stat3 (Fig. 3 B). Collectively, these results 
indicated that the levels of IL-17 positively correlated with 
Stat3 activity in growing tumors.
We next tested whether increased IL-17 expression af-
fected downstream Stat3 target genes. We found that Bcl 
family members, including Bcl-2 and Bcl-xL, were up-regu-
lated in tumors from IFN-/ mice (Fig. 3 C). In addition, 
vascular endothelial growth factor and MMP9 were up-reg-
ulated in tumors from IFN-/ mice, and their expression 
was reduced in tumors from IFN-/IL-17/ mice (Fig. 3 D). 
These results suggested that IL-17 promoted Stat3 activity in 
tumors, leading to up-regulation of antiapoptotic and angio-
genic genes.
To investigate whether IL-17 signals directly through 
Stat3, we cultured B16 tumor cells, normal fibroblasts, en-
dothelial cells, splenic DCs, and non-DC myeloid cells in 
the presence of recombinant mouse IL-17 or control. Re-
sults from these experiments showed that IL-17 indeed in-
duced Stat3 activity (Fig. 4 A). Although IL-17 induced 
Stat3 activity in all tested target cells, it did so with signifi-
cantly different kinetics (Fig. 4 A). Normal fibroblasts and 
endothelial cells were included to test IL-17 response, as 
they are major components of the tumor microenviron-
ment. Similarly, we found that human recombinant IL-17 
significantly  stimulated  Stat3  phosphorylation  in  several 
tumor-infiltrating Th17 cells (Fig. 2 A, top). IL-17 expression 
was also elevated in MB49 tumors grown in IFN-/ mice   
(Fig. 2 A, bottom). Further, ELISA analyses indicated a >10-
fold increase in secreted IL-17 by B16 tumor–infiltrating 
CD4+ T cells in IFN-/ mice, which was again abrogated 
in IFN-/IL-17/ double KO mice (Fig. 2 B). Notably, 
we observed only minimal levels of IL-17 production by 
CD8+ T cells in both B16 and MB49 tumors (Fig. S1).
We observed an increased infiltration of CD4+ and CD8+ 
T cells in tumors grown in IL-17/ mice (Fig. 2 C, top two 
rows). Furthermore, tumor-infiltrating CD8+ and CD4+ T 
cells from IL-17/ mice produced more IFN- relative to 
WT control mice, as assessed by intracellular cytokine stain-
ing (Fig. 2 C). The increase in IFN- production by both tu-
mor-infiltrating CD4+ and CD8+ T cells from IL-17/ mice 
was confirmed by ELISA (Fig. 2 D). IL-17 ablation only 
modestly increased the percentage of tumor-infiltrating regu-
latory T cells (Fig. S2 A). It has been reported that IL-17 abla-
tion does not affect the function of regulatory T cells (Yi   
et al., 2008). No correlation was observed with Th2-type im-
mune responses as measured by CD4+ T cell–mediated IL-4 
production caused by IL-17 and IFN- ablation (Fig. S2 B).
IL-17 activates Stat3 in both tumor and stromal cells  
in the tumor microenvironment
The underlying mechanisms by which Th17 promoted tu-
mor growth was still unknown. Because Stat3 activation in 
tumor cells and tumor-associated inflammatory cells plays a 
critical role in tumor progression by augmenting tumor sur-
vival and tumor angiogenesis, and suppressing antitumor im-
munity (Yu et al., 2007), we explored the possibility that 
IL-17 mediates tumor growth via activation of Stat3. Stat3 
activity in B16 tumors from WT, IL-17/, IFN-/, and 
IFN-/IL-17/ mice was examined by immunofluores-
Figure 3.  Tumorigenic effects of IL-17 are associated with Stat3 activation and up-regulation of oncogenic genes. B16 tumors were har-
vested from WT, IL-17/, IFN-/, and IFN-/IL-17/ mice 20 d after tumor challenge. (A and B) Stat3 activation in B16 tumors in vivo is notably 
diminished by IL-17 ablation. (A) Frozen tumor sections were stained with antibodies specific to phospho-Stat3 (pStat3; green). Results are representa-
tive of three independent experiments. Bar, 100 µm. (B) Western blot analysis of phospho-Stat3, total Stat3, and -actin in protein extracts prepared 
from freshly harvested B16 tumors (representative of three experiments). (C and D) IL-17 deletion inhibits expression of Stat3-downstream oncogenic 
genes. Western blot analysis of tumor protein extracts to detect Bcl-xL, Bcl-2, vascular endothelial growth factor, MMP9, and -actin protein levels 
(representative of two independent experiments).JEM VOL. 206, July 6, 2009  1461
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tumor cells with recombinant IL-17 only modestly increased 
their proliferation (Fig. S5 A), which is consistent with an-
other study (Numasaki et al., 2005), similar treatment of endo-
thelial cells led to increased expression of several Stat3 downstream 
genes that are involved in cell migration (Fig. S5 B). In addi-
tion, IL-17–mediated increased secretion of angiogenic fac-
tors by endothelial cells induced endothelial cell migration 
in a Stat3-dependent manner (Fig. S5 C). Importantly, neu-
tralizing IL-6 but not IL-10 (another Stat3 activator) with a 
blocking mAb reduced Stat3 activation in (mouse embry-
onic fibroblasts) MEFs, DCs, and MB49 tumor cells after 
IL-17 stimulation (Fig. 4 D). Similarly, anti–IL-6 antibodies 
abrogated IL-17–induced Stat3 activation in human cancer 
cells (Fig. S3 B). These results indicated that IL-17 activated 
Stat3 through IL-6 in diverse types of cancer and nontrans-
formed cells constituting the tumor stroma.
In vivo IL-6 blockade partially reverses tumor progression  
in the setting of high intratumoral IL-17
We first assessed whether IL-17 affected IL-6 production by 
tumors in vivo. Freshly harvested B16 tumor cells from WT 
human cancer cell lines (Fig. S3 A). We further confirmed 
the expression of IL-17 receptor in tumor cells and fibro-
blasts (Fig. S4). These results suggested that induction of 
Stat3 activation in tumor cells and elements of the tumor 
microenvironment by IL-17 occurred through induction 
of an intermediary factor rather than directly.
IL-17 activates Stat3 via IL-6 induction
IL-6 is a Stat3 activator and is elevated in diverse cancers 
(Hirano et al., 2000). IL-17 has recently been reported to 
stimulate production of IL-6 and Stat3 activation through   
a positive feedback loop, in inflammatory cells as well as   
fibroblasts, in an autoimmune disease setting (Ogura et al., 
2008). We therefore determined whether IL-6 mediated IL-
17–driven Stat3 activation in a tumor setting. We found that 
IL-17 stimulated IL-6 production by B16 and MB49 tumor 
cells in vitro, in addition to other cell types that constitute 
the tumor stroma such as fibroblasts, endothelial cells, and 
DCs (Fig. 4, B and C). The levels of IL-6 per cell produced 
by the tested tumor cells were lower than those produced   
by fibroblasts and endothelial cells. Although treating the 
Figure 4.  IL-17 activates Stat3 in tumor and tumor stromal cells through an IL-6–dependent mechanism. (A) The kinetics of Stat3 activation in 
B16 melanoma cells, MEFs, endothelial cells (ECP), splenic CD11c+ DCs, or splenic CD11b+ myeloid cells after stimulation with recombinant IL-17. Western 
blots of phospho-Stat3, total Stat3, and -actin are shown and are representative of two independent experiments. (B and C) IL-17 induces IL-6 expres-
sion in tumor and various tumor stromal cells. (B) IL-6 levels in B16 cells treated for 24 h with recombinant IL-17 were assessed by quantitative real-time 
PCR (left) and ELISA (second from left). IL-6 induction in MB49 tumor cells (middle), MEFs (second from right), and endothelial cells (ECP; right) by recom-
binant IL-17 treatment is shown (from three independent experiments; P < 0.0001). Data represent means ± SEM. (C) Production of IL-6 by CD11c+ DCs 
upon IL-17 stimulation, as determined by ELISA (from three independent experiments; P = 0.0002). Data represent means ± SEM. (D) IL-17–induced Stat3 
activation is IL-6 dependent. (top) MB49 tumor cells were incubated with IL-17 with or without anti–IL-6 or –IL-10 antibodies, and Western blots were 
performed for phospho-Stat3, total Stat3, and -actin protein levels. (bottom) MEFs and splenic CD11c+ DCs were stimulated with IL-17 in the presence 
of IL-6–neutralizing antibodies or control IgG (representative of three independent experiments).1462 TH17 RESPONSES PROMOTE TUMOR PROGRESSION VIA A STAT3 PATHWAY | Wang et al.
level of IL-6 when compared with the IFN-/IL-17/ 
mice (Fig. 5 A). More detailed analysis of growing tumors 
indicated that tumor-associated immune cells (CD45+) were 
the main source of IL-6 when compared with the tumor cells 
(Fig. 5 B). To directly test whether IL-17 could promote   
tumor  growth  through  IL-6–mediated  Stat3  activation,   
IFN-/ mice were challenged with B16 melanoma, fol-
lowed by administration of IL-6–neutralizing mAbs or con-
trol rat IgG. IFN-/IL-17/ mice challenged with B16 
melanoma but without anti–IL-6 antibody treatment were 
included as an additional control. Because IL-6 was shown to 
promote Th17 cell differentiation, we did not start anti–IL-6 
treatment until 6 d after tumor inoculation, a time at which 
tumor-infiltrating Th17 cells were detectable (unpublished 
data). We found that administration of monoclonal anti–IL-6 
but not rat IgG antibodies significantly inhibited tumor 
growth in IFN-/ mice (Fig. 5 C), suggesting that IL-17–
induced tumor progression is at least in part mediated by IL-6. 
Consistent with a role for IL-6 in mediating tumor Stat3 ac-
tivation and tumor growth promotion, neutralizing IL-6 in 
vivo reduced Stat3 activity and the expression of its down-
stream antiapoptotic gene, Bcl-xL, in tumors (Fig. 5 D).
In summary, we have shown that IL-17 can promote   
tumor growth. Our results suggested that the IL-17–medi-
ated tumor-promoting role involves a direct effect on tumor 
through IL-6 induction, which in turn activates Stat3 in 
both tumor as well as nontransformed cells constituting the 
tumor microenvironment. IL-6 activation of Stat3 in tumor 
cells results in increases in antiapoptotic, proproliferation, 
and proangiogenic genes, as well as suppression of certain 
proinflammatory genes (Yu et al., 2007). IL-6–induced Stat3 
signaling in T cells is also critical in promoting Th17 cell 
differentiation  and  expression  (Chen  et  al.,  2006;  Harris   
et al., 2007). Given that TGF-, the other cytokine involved 
in Th17 cell differentiation, is also expressed at high levels in 
tumors, IL-17–induced IL-6 production can generate an au-
toamplification loop for Th17 cells in the tumor microenvi-
ronment. Consistent with our findings, several publications 
suggested  a  role  of  IL-17  in  promoting  tumor  growth   
(Numasaki et al., 2003; Numasaki et al., 2005; Nam et al., 
2008; Xiao et al., 2009), although the mechanism was not 
well addressed in these studies. However, a recent paper 
showed that, in a different tumor system (MC38 sarcoma), 
tumors growth was increased in IL-17/ mice (Kryczek   
et al., 2009). These findings suggest that the role of IL-17 in 
cancer is context and system dependent, like many other cy-
tokines such as TNF-. Additional studies are required to 
reveal why IL-17 can have opposite roles in modulating 
growth in different tumor systems.
The opposing functions of IFN- and IL-17 as anticarci-
nogenic and protumor growth effector cytokines extend an 
emerging concept that the qualitative nature of the immune 
response determines whether it will predominantly inhibit 
tumor growth or promote cancer development. Recently, 
analogous opposing effects of the two IL-12 family mem-
bers, IL-12 and IL-23, in tumor inhibition versus promotion 
mice produced relatively high levels of IL-6, which were re-
duced after IL-17 ablation (Fig. 5 A). In addition, tumors 
grown  in  IFN-/  mice  produced  a  markedly  increased 
Figure 5.  Tumor-derived IL-6 mediates tumorigenic effects of IL-17. 
(A and B) IL-6 secretion in the tumor microenvironment correlates with IL-
17 levels. (A) Single-cell suspensions prepared from B16 tumors harvested 
from the indicated mice were cultured in vitro overnight; supernatants were 
then collected and assayed for IL-6 levels, combining four mice from two 
independent experiments (WT vs. IL-17/, P = 0.0026; IFN-/ vs. IFN-
/IL-17/, P = 0.005). Data are means ± SEM. (B) Single-cell suspensions 
prepared from MB49 tumors were enriched for CD45. Both CD45+ (immune 
cells) and CD45 (tumor cells) were cultured overnight before supernatants 
were collected for ELISA (n = 4 mice representing three independent experi-
ments; IFN-/ vs. IFN-/IL-17/, P = 0.03). Data are means ± SEM.  
(C) 105 B16 tumor cells were injected subcutaneously into IFN-/ and IFN-
/IL-17/ mice. 6 d after tumor implantation, tumor-bearing IFN-/ 
mice were treated with IL-6–neutralizing antibodies or control rat IgG every 
other day. Data are means ± SEM (n = 7 mice from two independent experi-
ments). (D) Western blot analyses of phospho-Stat3, total Stat3, Bcl-xL, and 
-actin levels from protein extracts prepared from B16 tumors harvested 
from the indicated mice (representative of two independent experiments).JEM VOL. 206, July 6, 2009  1463
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ELISA assays. 105 sorted tumor-infiltrating CD4+, CD8+ T cells were 
cultured for 24 h in a U-bottom 96-well plate with plate-bound CD3 and 
2 µg/ml of soluble CD28. 106 enriched splenic CD11c+ or cultured cells/ml 
were stimulated for 24 h with 10 ng/ml of recombinant IL-17. IFN-, IL-17, 
IL-6, and IL-4 concentrations in culture supernatants were measured using 
ELISA kits from R&D Systems.
Immunofluorescence  staining.  5-µm  sections  of  flash-frozen  tumor 
specimens were fixed in acetone, permeabilized with methanol, stained with 
antibodies specific to tyrosine–phospho-Stat3 (Santa Cruz Biotechnology, 
Inc.) and detected with secondary antibodies conjugated Alexa Fluor 488 
(Invitrogen), as previously described (Kortylewski et al., 2005). After stain-
ing with Hoechst 33342 (Invitrogen) to visualize cell nuclei, slides were 
mounted and analyzed by fluorescence microscopy.
Statistical analysis. The unpaired t test was used to calculate the two-
tailed p-value. The two-way analysis of variance test was used to calculate 
the p-value for tumor growth. Data were analyzed using Prism software 
(GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows the production of IL-17 in 
tumor-infiltrating CD8+ T cells, determined by intracellular staining and 
ELISA. Fig. S2 indicates that ablating IFN- or IL-17 did not significantly 
affect the T reg cell percentage and IL-4 production. Fig. S3 shows that IL-17 
activates Stat3 in human tumor cell lines in an IL-6–dependent manner.   
Fig. S4 confirms IL-17 receptor expression on B16 tumor cells and MEFs. 
Fig. S5 depicts the effect of IL-17 on tumor cell proliferation and endothelial 
cell migration. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20090207/DC1.
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